TABLE 4.

CA between Vitek 2 AF03 IUO yeast susceptibility test and CLSI BMD MICs of fluconazole for 698 Candida and 44 C. neoformans isolates when using new CBPs and ECVs

Species (no. of isolates tested) and test method	% of MICs by categorya			CA (%)	% VME	% ME	% Minor errors
	S	SDD	R
C. albicans (215)
Vitek 2	93.0	0.5	6.5
BMDb	94.4	3.3	2.3	94.9	0.0	2.3	2.8
C. glabrata (181)
Vitek 2		71.8	28.2
BMD		85.6	14.4	87.8	0.0	0.0	12.2
C. parapsilosis (109)
Vitek 2	85.3	0.9	13.8
BMD	83.5	3.7	12.8	94.5	1.8	0.9	2.8
C. tropicalis (107)
Vitek 2	86.0	1.9	12.1
BMD	87.9	6.5	5.6	90.6	0.0	4.7	4.7
C. krusei (30)
Vitek 2			100
BMD			100	100	0.0	0.0	0.0
C. lusitaniae (28)
Vitek 2	82.1		17.9
BMD	96.4		3.6	85.7	0.0	14.3
C. dubliniensis (13)
Vitek 2	84.6		15.4
BMD	100		0.0	84.6	0.0	15.4
C. guilliermondii (8)
Vitek 2	100		0.0
BMD	100		0.0	100	0.0	0.0
C. pelliculosa (4)
Vitek 2	100		0.0
BMD	100		0.0	100	0.0	0.0
C. kefyr (3)
Vitek 2	66.7		33.3
BMD	100		0.0	66.7	0.0	33.3
C. neoformans (44)
Vitek 2	84.1		15.9
BMD	90.9		9.1	84.1	4.5	11.4

^aThe CBPs for S, SDD, and R, respectively, were those of the CLSI of fluconazole for C. albicans, C. tropicalis, and C. parapsilosis (S, ≤2 μg/ml; SDD, 4 μg/ml; R, ≥8 μg/ml) and C. glabrata (SDD, ≤32 μg/ml; R, ≥64 μg/ml). There are no CBPs of fluconazole for C. krusei; all isolates are categorized as R irrespective of the MIC. Because of the lack of CBPs, the ECV was used to determine fluconazole S (WT) and R (non-WT) of C. lusitaniae (≤1 and ≥2 μg/ml), C. dubliniensis (≤0.5 and ≥1 μg/ml), C. guilliermondii (≤8 and ≥16 μg/ml), C. pelliculosa (≤4 and ≥8 μg/ml), C. kefyr (≤1 and ≥2 μg/ml), and C. neoformans (≤16 and ≥32 μg/ml).

^bThe CLSI BMD test result was read at either 24 h (Candida species) or 72 h (C. neoformans) of incubation.